We are very excited that we have finally crossed the finishing line and we are now launching, says Executive Chairman, Biocon.

You have launched glargine in the US. What significance does it have for the company?
This is a long awaited launch. This is a very important launch for us because it heralds our entry into the diabetes insulin space in the US which is a very important market for us. I think with the introduction of Semglee in the US market, this will open up a huge opportunity for Biocon. This is already a $6-billion market opportunity in terms of Lantus sales, but even as a biosimilar it is estimated to be a $2.2-billion opportunity for Biocon and Mylan. We are very excited that we have finally crossed the finishing line and we are now ready to launch.